QuidelOrtho Corp
QDEL29.810USD
+0.860+2.97%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
2.02BMarket Cap
LossP/E TTM
More Details of QuidelOrtho Corp Company
QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
QuidelOrtho Corp Info
Ticker SymbolQDEL
Company nameQuidelOrtho Corp
IPO dateFeb 01, 1991
CEOBlaser (Brian J)
Number of employees6600
Security typeOrdinary Share
Fiscal year-endFeb 01
Address9975 Summers Ridge Road
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18585521100
Websitehttps://www.quidelortho.com/
Ticker SymbolQDEL
IPO dateFeb 01, 1991
CEOBlaser (Brian J)
Company Executives of QuidelOrtho Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
104.41K
+9.68%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
72.55K
+7.29%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
33.58K
+75.18%
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
32.03K
+8.95%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
21.35K
+35.98%
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
15.02K
+5.26%
Mr. Brian J. Blaser
Mr. Brian J. Blaser
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.45K
--
Mr. John R. Chiminski
Mr. John R. Chiminski
Independent Director
Independent Director
2.52K
--
Sergio Gadaleta
Sergio Gadaleta
Senior Vice President - Clinical and Regulatory Affairs
Senior Vice President - Clinical and Regulatory Affairs
--
--
Devon Burek
Devon Burek
Senior Vice President - Global Quality
Senior Vice President - Global Quality
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
104.41K
+9.68%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
72.55K
+7.29%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
33.58K
+75.18%
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
32.03K
+8.95%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
21.35K
+35.98%
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
15.02K
+5.26%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Labs
369.70M
60.22%
Immunohematology
132.30M
21.55%
Point-of-Care
93.00M
15.15%
Donor Screening
13.30M
2.17%
Molecular Diagnostic Solutions
5.60M
0.91%
By RegionUSD
Name
Revenue
Proportion
North America
310.70M
50.61%
Other
132.50M
21.58%
EMEA
87.30M
14.22%
China
83.40M
13.59%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Labs
369.70M
60.22%
Immunohematology
132.30M
21.55%
Point-of-Care
93.00M
15.15%
Donor Screening
13.30M
2.17%
Molecular Diagnostic Solutions
5.60M
0.91%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
16.21%
BlackRock Institutional Trust Company, N.A.
13.72%
The Vanguard Group, Inc.
11.19%
Rubric Capital Management LP
6.83%
Fidelity Management & Research Company LLC
6.54%
Other
45.52%
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
16.21%
BlackRock Institutional Trust Company, N.A.
13.72%
The Vanguard Group, Inc.
11.19%
Rubric Capital Management LP
6.83%
Fidelity Management & Research Company LLC
6.54%
Other
45.52%
Shareholder Types
Shareholders
Proportion
Investment Advisor
68.41%
Investment Advisor/Hedge Fund
35.84%
Hedge Fund
14.73%
Research Firm
2.25%
Pension Fund
1.07%
Individual Investor
0.95%
Private Equity
0.76%
Bank and Trust
0.61%
Sovereign Wealth Fund
0.52%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
656
79.44M
116.95%
-23.17M
2025Q2
684
78.51M
115.63%
-21.42M
2025Q1
726
76.59M
113.26%
-21.60M
2024Q4
747
75.07M
111.30%
-13.02M
2024Q3
744
73.58M
109.44%
-4.02M
2024Q2
767
70.18M
104.79%
-7.57M
2024Q1
799
67.05M
100.24%
-5.28M
2023Q4
828
68.21M
102.09%
-2.95M
2023Q3
842
70.19M
105.17%
-4.01M
2023Q2
860
68.99M
103.61%
-6.94M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
T. Rowe Price Investment Management, Inc.
11.14M
16.4%
-310.96K
-2.72%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
9.28M
13.67%
+1.73M
+22.86%
Jun 30, 2025
The Vanguard Group, Inc.
7.77M
11.44%
+1.04M
+15.55%
Jun 30, 2025
Rubric Capital Management LP
4.64M
6.83%
-1.50M
-24.47%
Jun 30, 2025
Fidelity Management & Research Company LLC
2.56M
3.76%
+1.30M
+103.23%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.51M
3.69%
+691.35K
+38.04%
Jun 30, 2025
Newtyn Management, LLC
1.71M
2.51%
+490.67K
+40.38%
Jun 30, 2025
State Street Investment Management (US)
2.70M
3.98%
+510.29K
+23.29%
Jun 30, 2025
Invesco Advisers, Inc.
1.33M
1.96%
-2.27M
-63.07%
Jun 30, 2025
American Century Investment Management, Inc.
1.92M
2.82%
+327.00K
+20.58%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
State Street SPDR S&P Health Care Equipment ETF
1.75%
Invesco S&P SmallCap Health Care ETF
1.12%
Ballast Small/Mid Cap ETF
0.94%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.56%
JPMorgan Fundamental Data Science Small Core ETF
0.35%
State Street SPDR S&P 600 Small Cap Value ETF
0.26%
Avantis US Small Cap Value ETF
0.26%
iShares S&P Small-Cap 600 Value ETF
0.25%
iShares U.S. Medical Devices ETF
0.22%
State Street SPDR S&P SmallCap 600 ESG ETF
0.19%
View more
State Street SPDR S&P Health Care Equipment ETF
Proportion1.75%
Invesco S&P SmallCap Health Care ETF
Proportion1.12%
Ballast Small/Mid Cap ETF
Proportion0.94%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion0.56%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.35%
State Street SPDR S&P 600 Small Cap Value ETF
Proportion0.26%
Avantis US Small Cap Value ETF
Proportion0.26%
iShares S&P Small-Cap 600 Value ETF
Proportion0.25%
iShares U.S. Medical Devices ETF
Proportion0.22%
State Street SPDR S&P SmallCap 600 ESG ETF
Proportion0.19%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of QuidelOrtho Corp?
The top five shareholders of QuidelOrtho Corp are:
T. Rowe Price Investment Management, Inc. holds 11.14M shares, accounting for 16.40% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 9.28M shares, accounting for 13.67% of the total shares.
The Vanguard Group, Inc. holds 7.77M shares, accounting for 11.44% of the total shares.
Rubric Capital Management LP holds 4.64M shares, accounting for 6.83% of the total shares.
Fidelity Management & Research Company LLC holds 2.56M shares, accounting for 3.76% of the total shares.
T. Rowe Price Investment Management, Inc. holds 11.14M shares, accounting for 16.40% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 9.28M shares, accounting for 13.67% of the total shares.
The Vanguard Group, Inc. holds 7.77M shares, accounting for 11.44% of the total shares.
Rubric Capital Management LP holds 4.64M shares, accounting for 6.83% of the total shares.
Fidelity Management & Research Company LLC holds 2.56M shares, accounting for 3.76% of the total shares.
What are the top three shareholder types of QuidelOrtho Corp?
The top three shareholder types of QuidelOrtho Corp are:
T. Rowe Price Investment Management, Inc.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
T. Rowe Price Investment Management, Inc.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
How many institutions hold shares of QuidelOrtho Corp (QDEL)?
As of 2025Q3, 656 institutions hold shares of QuidelOrtho Corp, with a combined market value of approximately 79.44M, accounting for 116.95% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 1.32%.
What is the biggest source of revenue for QuidelOrtho Corp?
In FY2025Q2, the Labs business generated the highest revenue for QuidelOrtho Corp, amounting to 369.70M and accounting for 60.22% of total revenue.
